Evidence map›Paper›PMID 26481065›Full record

ArticleDevelopmental biology2016

Endoglin is required in Pax3-derived cells for embryonic blood vessel formation.

K Young, L T Krebs, E Tweedie, B Conley, M Mancini, H M Arthur, L Liaw, T Gridley, Cph Vary

Open access · greenAbstract read
In one paragraph

Article in Developmental biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

K YoungMaine Medical Center Research Institute, Scarborough, ME, United States; Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, United States; The Jackson Laboratory, Bar Harbor, ME, United States.
L T KrebsMaine Medical Center Research Institute, Scarborough, ME, United States.
E TweedieMaine Medical Center Research Institute, Scarborough, ME, United States.
B ConleyMaine Medical Center Research Institute, Scarborough, ME, United States.
M ManciniMaine Medical Center Research Institute, Scarborough, ME, United States; Champions Oncology, Baltimore, MD, United States.
H M ArthurInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
L LiawMaine Medical Center Research Institute, Scarborough, ME, United States; Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, United States.
T GridleyMaine Medical Center Research Institute, Scarborough, ME, United States; Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, United States.
Cph VaryMaine Medical Center Research Institute, Scarborough, ME, United States; Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, United States. Electronic address: varyc@mmc.org.
Maine Medical Center · USNewcastle University · GB

Funding

Transcriptional Decisions in Endothelial Cell DifferentiationP20RR015555 · NCRR · MAINE MEDICAL CENTER · PI PRUDOVSKY, IGOR · 2000 to 2009
$21.4M
Progenitor Cell Analysis CoreP30GM106391 · NIGMS · MAINEHEALTH · PI WOJCHOWSKI, DON MICHAEL · 2013 to 2017
$5.7M
Phase III COBRE in Vascular BiologyP30GM103392 · NIGMS · MAINEHEALTH · PI ST. GERMAIN, DONALD L. · 2012 to 2016
$4.7M
Regulation of TGF-beta Receptor-dependent Vascular DiseaseR01HL083151 · NHLBI · MAINEHEALTH · PI VARY, CALVIN PARDEE HULL · 2007 to 2011
$2.0M
Smooth muscle cell integration of differentiation signalsR01HL109652 · NHLBI · MAINEHEALTH · PI LIAW, LUCY · 2012 to 2015
$1.5M
British Heart Foundation PG/14/86/31177British Heart Foundation RG/12/2/29416NCRR NIH HHS P20 RR015555NCRR NIH HHS P20-RR-15555NHLBI NIH HHS 5R01HL10965NHLBI NIH HHS HL083151NHLBI NIH HHS R01 HL083151NHLBI NIH HHS R01 HL109652NIGMS NIH HHS P30 GM103392NIGMS NIH HHS P30 GM106391
6 · The paper itself

Abstract

Mutations in endoglin, a TGFβ/BMP coreceptor, are causal for hereditary hemorrhagic telangiectasia (HHT). Endoglin-null (Eng-/-) mouse embryos die at embryonic day (E)10.5-11.5 due to defects in angiogenesis. In part, this is due to an absence of vascular smooth muscle cell differentiation and vessel investment. Prior studies from our lab and others have shown the importance of endoglin expression in embryonic development in both endothelial cells and neural crest stem cells. These studies support the hypothesis that endoglin may play cell-autonomous roles in endothelial and vascular smooth muscle cell precursors. However, the requirement for endoglin in vascular cell precursors remains poorly defined. Our objective was to specifically delete endoglin in neural crest- and somite-derived Pax3-positive vascular precursors to understand the impact on somite progenitor cell contribution to embryonic vascular development. Pax3Cre mice were crossed with Eng+/- mice to obtain compound mutant Pax3(Cre/+);Eng+/- mice. These mice were then crossed with homozygous endoglin LoxP-mutated (Eng(LoxP/LoxP)) mice to conditionally delete the endoglin gene in specific lineages that contribute to endothelial and smooth muscle constituents of developing embryonic vessels. Pax3(Cre/+);Eng(LoxP/)(-) mice showed a variety of vascular defects at E10.5, and none of these mice survived past E12.5. Embryos analyzed at E10.5 showed malformations suggestive of misdirection of the intersomitic vessels. The dorsal aorta showed significant dilation with associated vascular smooth muscle cells exhibiting disorganization and enhanced expression of smooth muscle differentiation proteins, including smooth muscle actin. These results demonstrate a requirement for endoglin in descendants of Pax3-expressing vascular cell precursors, and thus provides new insight into the cellular basis underlying adult vascular diseases such as HHT.

Indexed as

Neovascularization, PhysiologicActinsAllelesAnimalsAortaBlood VesselsEmbryo LossEmbryo, MammalianEndoglinEndothelial CellsGene DeletionIntegrasesIntracellular Signaling Peptides and ProteinsMiceMuscle, Smooth, VascularMyocytes, Smooth MuscleActinsCre recombinaseEndoglinEng protein, mouseIntegrasesIntracellular Signaling Peptides and ProteinsPaired Box Transcription FactorsPax3 protein, mousePAX3 Transcription FactorDorsal aortaEndoglinHHTIntersomiticPax3Vascular malformation

Identifiers

PMID26481065
PMCPMC4688190
OpenAlexW1808392307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.